Nanotechnology for Diabetes Management:
A multidisciplinary approach to the latest developments of nanomedicine for the treatment of different facets of diabetes.
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Weitere Verfasser: | , , |
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Cambridge :
Royal Society of Chemistry,
2022.
|
| Schriftenreihe: | ISSN.
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | A multidisciplinary approach to the latest developments of nanomedicine for the treatment of different facets of diabetes. |
| Beschreibung: | Description based upon print version of record. 6.2.2 Physiological Barriers for Lung Absorption |
| Beschreibung: | 1 online resource (367 p.). |
| ISBN: | 1839165502 9781839165504 |
Internformat
MARC
| LEADER | 00000cam a2200000Mu 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-on1345586008 | ||
| 003 | OCoLC | ||
| 005 | 20241004212047.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 220924s2022 xx o ||| 0 eng d | ||
| 040 | |a EBLCP |b eng |c EBLCP |d N$T |d OCLCF |d OCLCO | ||
| 020 | |a 1839165502 | ||
| 020 | |a 9781839165504 |q (electronic bk.) | ||
| 035 | |a (OCoLC)1345586008 | ||
| 050 | 4 | |a RC660 | |
| 082 | 7 | |a 616.46206 |2 23 | |
| 049 | |a MAIN | ||
| 100 | 1 | |a Abderrahmani, Amar. | |
| 245 | 1 | 0 | |a Nanotechnology for Diabetes Management |h [electronic resource]. |
| 260 | |a Cambridge : |b Royal Society of Chemistry, |c 2022. | ||
| 300 | |a 1 online resource (367 p.). | ||
| 490 | 1 | |a ISSN | |
| 500 | |a Description based upon print version of record. | ||
| 505 | 0 | |a Intro -- Title -- Copyright -- Contents -- Chapter 1: Chemical Approaches for Beta-cell Biology -- 1.1 Introduction -- 1.2 Principles of Chemical Biology -- 1.3 High-throughput Screening (HTS) -- 1.4 Target-based Screening -- 1.5 Phenotypic Screening -- 1.5.1 Hit Triage -- 1.5.2 The Sources of Chemical Probes -- 1.5.3 Target Identification and Mechanism-of-action Studies -- 1.6 The Chemical Biology of Diabetes -- 1.6.1 Type 1 Diabetes (T1D) -- 1.6.2 Type 2 Diabetes (T2D) -- 1.6.3 Modeling the Beta Cell for Small-molecule Discovery -- 1.7 Therapeutic Approaches in the Beta Cell | |
| 505 | 8 | |a 1.7.1 First-generation Therapeutics -- 1.7.2 Second-generation Therapeutics -- 1.7.3 New Therapeutic Approaches -- 1.7.4 Emerging Therapeutic Approaches -- 1.8 Selectively Targeting the Beta Cell -- 1.8.1 Need for Beta-cell Targeting Moieties -- 1.8.2 Beta-cell Targeting -- 1.8.3 Next Steps Toward Selective Targeting -- Abbreviations -- References -- Chapter 2: Epigenomics of Type 2 Diabetes -- 2.1 Introduction -- 2.2 Epigenetics, Gene-Environment Interactions, and Diabetes Risk -- 2.3 Epigenetics and the Developmental Basis of Diabetes Risk | |
| 505 | 8 | |a 2.3.1 Gametes, Early Embryonic Development, and Transmission of Disease Risk -- 2.4 Epigenome-wide Association Studies (EWAS) for T2D -- 2.4.1 Methods for Epigenomic Profiling -- 2.4.2 Epigenetic Mechanisms of Beta-cell Failure -- 2.4.3 Epigenetics of Obesity and Insulin Resistance -- 2.4.4 Epigenetic Dysregulation as a Mediator of Diabetes Complications -- 2.5 Extracellular Vesicles, the Epigenome, and Diabetes Pathogenesis -- 2.6 Epigenetic Biomarkers and Therapies -- 2.7 Conclusions -- Acknowledgements -- References | |
| 505 | 8 | |a Chapter 3: Optimizing the Current Type 2 Diabetes Antidiabetics with Nanotechnologies: Where Do We Stand? -- 3.1 Introduction -- 3.2 Biguanides -- 3.3 Sulfonylureas -- 3.4 Glinides -- 3.5 GLP-1 Receptor Agonists -- 3.6 Dipeptidyl Peptidase-4 (DDP-4) Inhibitors -- 3.7 Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2i) -- 3.8 Basal Insulin -- 3.9 Conclusion -- Acknowledgements -- References -- Chapter 4: Amyloidosis Inhibition and Detection of Human Islet Amyloid Polypeptide with Nanomaterials -- 4.1 Introduction -- 4.2 IAPP Amyloidosis -- 4.3 Inhibition of IAPP Amyloidosis | |
| 505 | 8 | |a 4.4 Nanoprobes for the Detection and Imaging of IAPP Amyloid Deposits -- 4.5 Summary and Outlook -- References -- Chapter 5: Phytochemicals in the Management of Diabetes -- 5.1 Introduction -- 5.2 Anti-diabetic Effects of Phytochemicals on Humans (Clinical Trials) -- 5.3 Effects of Phytochemicals In Vivo -- 5.3.1 Oligonol -- 5.4 Effects of Phytochemicals In Vitro -- 5.5 Conclusion and Perspectives -- References -- Chapter 6: Inhalation of Insulin for Diabetes Management -- 6.1 Introduction -- 6.2 Inhalation Route -- 6.2.1 Respiratory System Anatomy and Physiology | |
| 500 | |a 6.2.2 Physiological Barriers for Lung Absorption | ||
| 520 | |a A multidisciplinary approach to the latest developments of nanomedicine for the treatment of different facets of diabetes. | ||
| 650 | 0 | |a Diabetes |x Treatment. | |
| 650 | 0 | |a Nanotechnology |x Therapeutic use. | |
| 650 | 6 | |a Nanotechnologie |x Emploi en thérapeutique. | |
| 650 | 7 | |a Diabetes |x Treatment |2 fast | |
| 700 | 1 | |a Szunerits, Sabine. | |
| 700 | 1 | |a Boukerroub, Rabah. | |
| 700 | 1 | |a El Ouaamari, Abdelfattah. | |
| 776 | 0 | 8 | |i Print version: |a Abderrahmani, Amar |t Nanotechnology for Diabetes Management |d Cambridge : Royal Society of Chemistry,c2022 |z 9781839164705 |
| 830 | 0 | |a ISSN. | |
| 856 | 4 | 0 | |l FWS01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=3391639 |3 Volltext |
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL7098864 | ||
| 938 | |a EBSCOhost |b EBSC |n 3391639 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBA-on1345586008 |
|---|---|
| _version_ | 1816882565098766336 |
| adam_text | |
| any_adam_object | |
| author | Abderrahmani, Amar |
| author2 | Szunerits, Sabine Boukerroub, Rabah El Ouaamari, Abdelfattah |
| author2_role | |
| author2_variant | s s ss r b rb o a e oa oae |
| author_facet | Abderrahmani, Amar Szunerits, Sabine Boukerroub, Rabah El Ouaamari, Abdelfattah |
| author_role | |
| author_sort | Abderrahmani, Amar |
| author_variant | a a aa |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | R - Medicine |
| callnumber-label | RC660 |
| callnumber-raw | RC660 |
| callnumber-search | RC660 |
| callnumber-sort | RC 3660 |
| callnumber-subject | RC - Internal Medicine |
| collection | ZDB-4-EBA |
| contents | Intro -- Title -- Copyright -- Contents -- Chapter 1: Chemical Approaches for Beta-cell Biology -- 1.1 Introduction -- 1.2 Principles of Chemical Biology -- 1.3 High-throughput Screening (HTS) -- 1.4 Target-based Screening -- 1.5 Phenotypic Screening -- 1.5.1 Hit Triage -- 1.5.2 The Sources of Chemical Probes -- 1.5.3 Target Identification and Mechanism-of-action Studies -- 1.6 The Chemical Biology of Diabetes -- 1.6.1 Type 1 Diabetes (T1D) -- 1.6.2 Type 2 Diabetes (T2D) -- 1.6.3 Modeling the Beta Cell for Small-molecule Discovery -- 1.7 Therapeutic Approaches in the Beta Cell 1.7.1 First-generation Therapeutics -- 1.7.2 Second-generation Therapeutics -- 1.7.3 New Therapeutic Approaches -- 1.7.4 Emerging Therapeutic Approaches -- 1.8 Selectively Targeting the Beta Cell -- 1.8.1 Need for Beta-cell Targeting Moieties -- 1.8.2 Beta-cell Targeting -- 1.8.3 Next Steps Toward Selective Targeting -- Abbreviations -- References -- Chapter 2: Epigenomics of Type 2 Diabetes -- 2.1 Introduction -- 2.2 Epigenetics, Gene-Environment Interactions, and Diabetes Risk -- 2.3 Epigenetics and the Developmental Basis of Diabetes Risk 2.3.1 Gametes, Early Embryonic Development, and Transmission of Disease Risk -- 2.4 Epigenome-wide Association Studies (EWAS) for T2D -- 2.4.1 Methods for Epigenomic Profiling -- 2.4.2 Epigenetic Mechanisms of Beta-cell Failure -- 2.4.3 Epigenetics of Obesity and Insulin Resistance -- 2.4.4 Epigenetic Dysregulation as a Mediator of Diabetes Complications -- 2.5 Extracellular Vesicles, the Epigenome, and Diabetes Pathogenesis -- 2.6 Epigenetic Biomarkers and Therapies -- 2.7 Conclusions -- Acknowledgements -- References Chapter 3: Optimizing the Current Type 2 Diabetes Antidiabetics with Nanotechnologies: Where Do We Stand? -- 3.1 Introduction -- 3.2 Biguanides -- 3.3 Sulfonylureas -- 3.4 Glinides -- 3.5 GLP-1 Receptor Agonists -- 3.6 Dipeptidyl Peptidase-4 (DDP-4) Inhibitors -- 3.7 Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2i) -- 3.8 Basal Insulin -- 3.9 Conclusion -- Acknowledgements -- References -- Chapter 4: Amyloidosis Inhibition and Detection of Human Islet Amyloid Polypeptide with Nanomaterials -- 4.1 Introduction -- 4.2 IAPP Amyloidosis -- 4.3 Inhibition of IAPP Amyloidosis 4.4 Nanoprobes for the Detection and Imaging of IAPP Amyloid Deposits -- 4.5 Summary and Outlook -- References -- Chapter 5: Phytochemicals in the Management of Diabetes -- 5.1 Introduction -- 5.2 Anti-diabetic Effects of Phytochemicals on Humans (Clinical Trials) -- 5.3 Effects of Phytochemicals In Vivo -- 5.3.1 Oligonol -- 5.4 Effects of Phytochemicals In Vitro -- 5.5 Conclusion and Perspectives -- References -- Chapter 6: Inhalation of Insulin for Diabetes Management -- 6.1 Introduction -- 6.2 Inhalation Route -- 6.2.1 Respiratory System Anatomy and Physiology |
| ctrlnum | (OCoLC)1345586008 |
| dewey-full | 616.46206 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.46206 |
| dewey-search | 616.46206 |
| dewey-sort | 3616.46206 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04540cam a2200493Mu 4500</leader><controlfield tag="001">ZDB-4-EBA-on1345586008</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr cnu---unuuu</controlfield><controlfield tag="008">220924s2022 xx o ||| 0 eng d</controlfield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">EBLCP</subfield><subfield code="b">eng</subfield><subfield code="c">EBLCP</subfield><subfield code="d">N$T</subfield><subfield code="d">OCLCF</subfield><subfield code="d">OCLCO</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1839165502</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781839165504</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1345586008</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RC660</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">616.46206</subfield><subfield code="2">23</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Abderrahmani, Amar.</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Nanotechnology for Diabetes Management</subfield><subfield code="h">[electronic resource].</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Cambridge :</subfield><subfield code="b">Royal Society of Chemistry,</subfield><subfield code="c">2022.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (367 p.).</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">ISSN</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Description based upon print version of record.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Intro -- Title -- Copyright -- Contents -- Chapter 1: Chemical Approaches for Beta-cell Biology -- 1.1 Introduction -- 1.2 Principles of Chemical Biology -- 1.3 High-throughput Screening (HTS) -- 1.4 Target-based Screening -- 1.5 Phenotypic Screening -- 1.5.1 Hit Triage -- 1.5.2 The Sources of Chemical Probes -- 1.5.3 Target Identification and Mechanism-of-action Studies -- 1.6 The Chemical Biology of Diabetes -- 1.6.1 Type 1 Diabetes (T1D) -- 1.6.2 Type 2 Diabetes (T2D) -- 1.6.3 Modeling the Beta Cell for Small-molecule Discovery -- 1.7 Therapeutic Approaches in the Beta Cell</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">1.7.1 First-generation Therapeutics -- 1.7.2 Second-generation Therapeutics -- 1.7.3 New Therapeutic Approaches -- 1.7.4 Emerging Therapeutic Approaches -- 1.8 Selectively Targeting the Beta Cell -- 1.8.1 Need for Beta-cell Targeting Moieties -- 1.8.2 Beta-cell Targeting -- 1.8.3 Next Steps Toward Selective Targeting -- Abbreviations -- References -- Chapter 2: Epigenomics of Type 2 Diabetes -- 2.1 Introduction -- 2.2 Epigenetics, Gene-Environment Interactions, and Diabetes Risk -- 2.3 Epigenetics and the Developmental Basis of Diabetes Risk</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">2.3.1 Gametes, Early Embryonic Development, and Transmission of Disease Risk -- 2.4 Epigenome-wide Association Studies (EWAS) for T2D -- 2.4.1 Methods for Epigenomic Profiling -- 2.4.2 Epigenetic Mechanisms of Beta-cell Failure -- 2.4.3 Epigenetics of Obesity and Insulin Resistance -- 2.4.4 Epigenetic Dysregulation as a Mediator of Diabetes Complications -- 2.5 Extracellular Vesicles, the Epigenome, and Diabetes Pathogenesis -- 2.6 Epigenetic Biomarkers and Therapies -- 2.7 Conclusions -- Acknowledgements -- References</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Chapter 3: Optimizing the Current Type 2 Diabetes Antidiabetics with Nanotechnologies: Where Do We Stand? -- 3.1 Introduction -- 3.2 Biguanides -- 3.3 Sulfonylureas -- 3.4 Glinides -- 3.5 GLP-1 Receptor Agonists -- 3.6 Dipeptidyl Peptidase-4 (DDP-4) Inhibitors -- 3.7 Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2i) -- 3.8 Basal Insulin -- 3.9 Conclusion -- Acknowledgements -- References -- Chapter 4: Amyloidosis Inhibition and Detection of Human Islet Amyloid Polypeptide with Nanomaterials -- 4.1 Introduction -- 4.2 IAPP Amyloidosis -- 4.3 Inhibition of IAPP Amyloidosis</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">4.4 Nanoprobes for the Detection and Imaging of IAPP Amyloid Deposits -- 4.5 Summary and Outlook -- References -- Chapter 5: Phytochemicals in the Management of Diabetes -- 5.1 Introduction -- 5.2 Anti-diabetic Effects of Phytochemicals on Humans (Clinical Trials) -- 5.3 Effects of Phytochemicals In Vivo -- 5.3.1 Oligonol -- 5.4 Effects of Phytochemicals In Vitro -- 5.5 Conclusion and Perspectives -- References -- Chapter 6: Inhalation of Insulin for Diabetes Management -- 6.1 Introduction -- 6.2 Inhalation Route -- 6.2.1 Respiratory System Anatomy and Physiology</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">6.2.2 Physiological Barriers for Lung Absorption</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">A multidisciplinary approach to the latest developments of nanomedicine for the treatment of different facets of diabetes.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Diabetes</subfield><subfield code="x">Treatment.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Nanotechnology</subfield><subfield code="x">Therapeutic use.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Nanotechnologie</subfield><subfield code="x">Emploi en thérapeutique.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Diabetes</subfield><subfield code="x">Treatment</subfield><subfield code="2">fast</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Szunerits, Sabine.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Boukerroub, Rabah.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">El Ouaamari, Abdelfattah.</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="a">Abderrahmani, Amar</subfield><subfield code="t">Nanotechnology for Diabetes Management</subfield><subfield code="d">Cambridge : Royal Society of Chemistry,c2022</subfield><subfield code="z">9781839164705</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">ISSN.</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=3391639</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ProQuest Ebook Central</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL7098864</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">3391639</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| id | ZDB-4-EBA-on1345586008 |
| illustrated | Not Illustrated |
| indexdate | 2024-11-27T13:30:38Z |
| institution | BVB |
| isbn | 1839165502 9781839165504 |
| language | English |
| oclc_num | 1345586008 |
| open_access_boolean | |
| owner | MAIN DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-863 DE-BY-FWS |
| physical | 1 online resource (367 p.). |
| psigel | ZDB-4-EBA |
| publishDate | 2022 |
| publishDateSearch | 2022 |
| publishDateSort | 2022 |
| publisher | Royal Society of Chemistry, |
| record_format | marc |
| series | ISSN. |
| series2 | ISSN |
| spelling | Abderrahmani, Amar. Nanotechnology for Diabetes Management [electronic resource]. Cambridge : Royal Society of Chemistry, 2022. 1 online resource (367 p.). ISSN Description based upon print version of record. Intro -- Title -- Copyright -- Contents -- Chapter 1: Chemical Approaches for Beta-cell Biology -- 1.1 Introduction -- 1.2 Principles of Chemical Biology -- 1.3 High-throughput Screening (HTS) -- 1.4 Target-based Screening -- 1.5 Phenotypic Screening -- 1.5.1 Hit Triage -- 1.5.2 The Sources of Chemical Probes -- 1.5.3 Target Identification and Mechanism-of-action Studies -- 1.6 The Chemical Biology of Diabetes -- 1.6.1 Type 1 Diabetes (T1D) -- 1.6.2 Type 2 Diabetes (T2D) -- 1.6.3 Modeling the Beta Cell for Small-molecule Discovery -- 1.7 Therapeutic Approaches in the Beta Cell 1.7.1 First-generation Therapeutics -- 1.7.2 Second-generation Therapeutics -- 1.7.3 New Therapeutic Approaches -- 1.7.4 Emerging Therapeutic Approaches -- 1.8 Selectively Targeting the Beta Cell -- 1.8.1 Need for Beta-cell Targeting Moieties -- 1.8.2 Beta-cell Targeting -- 1.8.3 Next Steps Toward Selective Targeting -- Abbreviations -- References -- Chapter 2: Epigenomics of Type 2 Diabetes -- 2.1 Introduction -- 2.2 Epigenetics, Gene-Environment Interactions, and Diabetes Risk -- 2.3 Epigenetics and the Developmental Basis of Diabetes Risk 2.3.1 Gametes, Early Embryonic Development, and Transmission of Disease Risk -- 2.4 Epigenome-wide Association Studies (EWAS) for T2D -- 2.4.1 Methods for Epigenomic Profiling -- 2.4.2 Epigenetic Mechanisms of Beta-cell Failure -- 2.4.3 Epigenetics of Obesity and Insulin Resistance -- 2.4.4 Epigenetic Dysregulation as a Mediator of Diabetes Complications -- 2.5 Extracellular Vesicles, the Epigenome, and Diabetes Pathogenesis -- 2.6 Epigenetic Biomarkers and Therapies -- 2.7 Conclusions -- Acknowledgements -- References Chapter 3: Optimizing the Current Type 2 Diabetes Antidiabetics with Nanotechnologies: Where Do We Stand? -- 3.1 Introduction -- 3.2 Biguanides -- 3.3 Sulfonylureas -- 3.4 Glinides -- 3.5 GLP-1 Receptor Agonists -- 3.6 Dipeptidyl Peptidase-4 (DDP-4) Inhibitors -- 3.7 Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2i) -- 3.8 Basal Insulin -- 3.9 Conclusion -- Acknowledgements -- References -- Chapter 4: Amyloidosis Inhibition and Detection of Human Islet Amyloid Polypeptide with Nanomaterials -- 4.1 Introduction -- 4.2 IAPP Amyloidosis -- 4.3 Inhibition of IAPP Amyloidosis 4.4 Nanoprobes for the Detection and Imaging of IAPP Amyloid Deposits -- 4.5 Summary and Outlook -- References -- Chapter 5: Phytochemicals in the Management of Diabetes -- 5.1 Introduction -- 5.2 Anti-diabetic Effects of Phytochemicals on Humans (Clinical Trials) -- 5.3 Effects of Phytochemicals In Vivo -- 5.3.1 Oligonol -- 5.4 Effects of Phytochemicals In Vitro -- 5.5 Conclusion and Perspectives -- References -- Chapter 6: Inhalation of Insulin for Diabetes Management -- 6.1 Introduction -- 6.2 Inhalation Route -- 6.2.1 Respiratory System Anatomy and Physiology 6.2.2 Physiological Barriers for Lung Absorption A multidisciplinary approach to the latest developments of nanomedicine for the treatment of different facets of diabetes. Diabetes Treatment. Nanotechnology Therapeutic use. Nanotechnologie Emploi en thérapeutique. Diabetes Treatment fast Szunerits, Sabine. Boukerroub, Rabah. El Ouaamari, Abdelfattah. Print version: Abderrahmani, Amar Nanotechnology for Diabetes Management Cambridge : Royal Society of Chemistry,c2022 9781839164705 ISSN. FWS01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=3391639 Volltext |
| spellingShingle | Abderrahmani, Amar Nanotechnology for Diabetes Management ISSN. Intro -- Title -- Copyright -- Contents -- Chapter 1: Chemical Approaches for Beta-cell Biology -- 1.1 Introduction -- 1.2 Principles of Chemical Biology -- 1.3 High-throughput Screening (HTS) -- 1.4 Target-based Screening -- 1.5 Phenotypic Screening -- 1.5.1 Hit Triage -- 1.5.2 The Sources of Chemical Probes -- 1.5.3 Target Identification and Mechanism-of-action Studies -- 1.6 The Chemical Biology of Diabetes -- 1.6.1 Type 1 Diabetes (T1D) -- 1.6.2 Type 2 Diabetes (T2D) -- 1.6.3 Modeling the Beta Cell for Small-molecule Discovery -- 1.7 Therapeutic Approaches in the Beta Cell 1.7.1 First-generation Therapeutics -- 1.7.2 Second-generation Therapeutics -- 1.7.3 New Therapeutic Approaches -- 1.7.4 Emerging Therapeutic Approaches -- 1.8 Selectively Targeting the Beta Cell -- 1.8.1 Need for Beta-cell Targeting Moieties -- 1.8.2 Beta-cell Targeting -- 1.8.3 Next Steps Toward Selective Targeting -- Abbreviations -- References -- Chapter 2: Epigenomics of Type 2 Diabetes -- 2.1 Introduction -- 2.2 Epigenetics, Gene-Environment Interactions, and Diabetes Risk -- 2.3 Epigenetics and the Developmental Basis of Diabetes Risk 2.3.1 Gametes, Early Embryonic Development, and Transmission of Disease Risk -- 2.4 Epigenome-wide Association Studies (EWAS) for T2D -- 2.4.1 Methods for Epigenomic Profiling -- 2.4.2 Epigenetic Mechanisms of Beta-cell Failure -- 2.4.3 Epigenetics of Obesity and Insulin Resistance -- 2.4.4 Epigenetic Dysregulation as a Mediator of Diabetes Complications -- 2.5 Extracellular Vesicles, the Epigenome, and Diabetes Pathogenesis -- 2.6 Epigenetic Biomarkers and Therapies -- 2.7 Conclusions -- Acknowledgements -- References Chapter 3: Optimizing the Current Type 2 Diabetes Antidiabetics with Nanotechnologies: Where Do We Stand? -- 3.1 Introduction -- 3.2 Biguanides -- 3.3 Sulfonylureas -- 3.4 Glinides -- 3.5 GLP-1 Receptor Agonists -- 3.6 Dipeptidyl Peptidase-4 (DDP-4) Inhibitors -- 3.7 Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2i) -- 3.8 Basal Insulin -- 3.9 Conclusion -- Acknowledgements -- References -- Chapter 4: Amyloidosis Inhibition and Detection of Human Islet Amyloid Polypeptide with Nanomaterials -- 4.1 Introduction -- 4.2 IAPP Amyloidosis -- 4.3 Inhibition of IAPP Amyloidosis 4.4 Nanoprobes for the Detection and Imaging of IAPP Amyloid Deposits -- 4.5 Summary and Outlook -- References -- Chapter 5: Phytochemicals in the Management of Diabetes -- 5.1 Introduction -- 5.2 Anti-diabetic Effects of Phytochemicals on Humans (Clinical Trials) -- 5.3 Effects of Phytochemicals In Vivo -- 5.3.1 Oligonol -- 5.4 Effects of Phytochemicals In Vitro -- 5.5 Conclusion and Perspectives -- References -- Chapter 6: Inhalation of Insulin for Diabetes Management -- 6.1 Introduction -- 6.2 Inhalation Route -- 6.2.1 Respiratory System Anatomy and Physiology Diabetes Treatment. Nanotechnology Therapeutic use. Nanotechnologie Emploi en thérapeutique. Diabetes Treatment fast |
| title | Nanotechnology for Diabetes Management |
| title_auth | Nanotechnology for Diabetes Management |
| title_exact_search | Nanotechnology for Diabetes Management |
| title_full | Nanotechnology for Diabetes Management [electronic resource]. |
| title_fullStr | Nanotechnology for Diabetes Management [electronic resource]. |
| title_full_unstemmed | Nanotechnology for Diabetes Management [electronic resource]. |
| title_short | Nanotechnology for Diabetes Management |
| title_sort | nanotechnology for diabetes management |
| topic | Diabetes Treatment. Nanotechnology Therapeutic use. Nanotechnologie Emploi en thérapeutique. Diabetes Treatment fast |
| topic_facet | Diabetes Treatment. Nanotechnology Therapeutic use. Nanotechnologie Emploi en thérapeutique. Diabetes Treatment |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=3391639 |
| work_keys_str_mv | AT abderrahmaniamar nanotechnologyfordiabetesmanagement AT szuneritssabine nanotechnologyfordiabetesmanagement AT boukerroubrabah nanotechnologyfordiabetesmanagement AT elouaamariabdelfattah nanotechnologyfordiabetesmanagement |